We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in F-star Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 59 → 0 (-59)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $57.8M → $0 (-$57.8M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 59

Holders
–
Holders Change
-59
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
59
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$6.32M
2
RSCM
Rock Springs Capital Management
Maryland
-$4.75M
3
TC
Trium Capital
United Kingdom
-$4.3M
4
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
-$3.79M
5
DCM
DAFNA Capital Management
California
-$3.65M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
– -$6.32M -1,000,000 Closed
RSCM
2
Rock Springs Capital Management
Maryland
– -$4.75M -751,889 Closed
TC
3
Trium Capital
United Kingdom
– -$4.3M -679,744 Closed
AVLSA
4
Atlas Venture Life Science Advisors
Massachusetts
– -$3.79M -599,524 Closed
DCM
5
DAFNA Capital Management
California
– -$3.65M -576,881 Closed
AVA
6
Atlas Venture Advisors
Massachusetts
– -$3.63M -574,996 Closed
WAM
7
Weiss Asset Management
Massachusetts
– -$3.46M -548,189 Closed
Russell Investments Group
8
Russell Investments Group
United Kingdom
– -$2.73M -432,125 Closed
CM
9
Crystalline Management
Canada
– -$2.37M -375,000 Closed
BlackRock
10
BlackRock
New York
– -$1.88M -297,433 Closed
Vanguard Group
11
Vanguard Group
Pennsylvania
– -$1.85M -292,664 Closed
Barclays
12
Barclays
United Kingdom
– -$1.43M -226,433 Closed
Citigroup
13
Citigroup
New York
– -$1.3M -206,400 Closed
GF
14
Gabelli Funds
New York
– -$1.29M -204,651 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$1.18M -185,982 Closed
QOP
16
Quinn Opportunity Partners
Virginia
– -$1.14M -179,705 Closed
Renaissance Technologies
17
Renaissance Technologies
New York
– -$1.09M -171,911 Closed
M
18
Murchinson
Ontario, Canada
– -$1.05M -166,906 Closed
GCIA
19
Gabelli & Co Investment Advisers
New York
– -$898K -142,110 Closed
BCM
20
BCK Capital Management
Connecticut
– -$869K -137,459 Closed
VAM
21
Vazirani Asset Management
New York
– -$790K -125,000 Closed
Goldman Sachs
22
Goldman Sachs
New York
– -$662K -104,690 Closed
Jane Street
23
Jane Street
New York
– -$620K -98,099 Closed
BFM
24
Boothbay Fund Management
New York
– -$527K -83,454 Closed
State Street
25
State Street
Massachusetts
– -$429K -67,950 Closed
1
2 3

FSTX Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2023, worth a combined $0 — down 100% from $57.8M a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of FSTX and 0 opened new positions — a net loss of 59 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Armistice Capital, exiting entirely with an estimated $6.32M sold.

  • 0 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2023, down from 59 in Q4 2022.
  • Funds reported $0 of F-star Therapeutics, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2023 and 59 closed out, a net change of -59 holders.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2023 was Armistice Capital, an estimated $6.32M sold.

Based on aggregated 13F filings for Q1 2023.